key: cord-0762094-xgnu48ag
authors: AL-LAMI, Rasha A.
title: Letter to the editor re: COVID-19 Vaccines in Pregnancy
date: 2021-02-20
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100336
sha: 11bd095738c224bba6aa53cb0fe4e10ed2458263
doc_id: 762094
cord_uid: xgnu48ag

nan

ACE-2 receptor, to which the spike protein of SARS-CoV-2 virus attaches to enter the cell, is found in the human uterus and is highly expressed during pregnancy (at least in the second half of pregnancy) to supply vasodilatory Angiotensin 1-7 that counteract uterine contraction. 2 Once SARS-CoV-2 virus attaches to ACE-2 receptor, ACE-2 receptor will be downregulated with subsequent reduction in the production of vasodilatory Angiotensin 1-7. 3 Interestingly, uterine contraction was found in animals after uterine ACE-2 receptor was knocked out. 4 To date, COVID-19 confirmed pregnant women were found to have high rate of preterm birth but uncertainty remains on the causal relationship between COVID-19 infection and the initiation of preterm labor. 5 mRNA-based vaccine of COVID-19 encodes the mRNA of SARS-CoV-2 spike protein.

After administrating COVID-19 mRNA-based vaccine, the mRNA of SARS-CoV-2 spike protein is read by self-cells (e.g., antigen presenting cells) where they can translate this mRNA and express the spike protein on their surface. However, it is unknown if the spike-protein expressing self-cells can escape the reticuloendothelial system and be present in the circulation.

Moreover, the affinity of these spike-protein expressing self-cells to ACE-2 receptors (including uterine ACE-2 receptors) remains uncertain.

Pregnant individuals receiving mRNA-based vaccine should be counseled on available safety assessment applications and encouraged to report any noticeable adverse events, especially abdominal pain that resembles uterine contraction, after being vaccinated. The CDC has launched a user-friendly smartphone-based application (V-SAFE, https://vsafe.cdc.gov/) that can be quickly used to report any side effects of COVID-19 vaccines. Moreover, health care providers should follow-up and monitor pregnant patients closely after they receive the vaccine.

Further, health care workers and vaccinated individuals can use the existing governmental tools to report any post vaccination adverse events (e.g, VAERS, https://vaers.hhs.gov/esub/index.jsp).

Although Moderna does not have a specific tool to report its vaccine side effects, Pfizer-BioNTech has developed a reporting portal that patients or healthcare providers can use to report any side effects noticed after getting Pfizer-BioNTech COVID-19 vaccine (https://www.pfizersafetyreporting.com/).

In sum, although the benefits of COVID-19 vaccines outweigh the risk of COVID-19 infection in pregnant women, data on safety of these vaccines in pregnant women should be urgently released.

COVID-19 Vaccines in Pregnancy

Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic? Life sciences

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Uterine artery dysfunction in pregnant ACE2 knockout mice is associated with placental hypoxia and reduced umbilical blood flow velocity

Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth

Special thanks to Scott C. Weaver, MS, PhD and Alan D. Barrett, PhD, from the University of Texas Medical Branch at Galveston for their scientific opinion.